Medtronic计划把糖尿病生意 转成一家新公司 来提升金融业绩 Medtronic plans to spin off its diabetes business into a new company to boost financial performance.

Medtronic医疗设备公司计划将其糖尿病业务分为一家名为“新糖尿病公司”的新独立公司, Medical device company Medtronic plans to separate its diabetes business into a new standalone company, named "New Diabetes Company," to focus on its high-margin markets. 预计将在18个月内通过IPO完成的分拆,旨在通过提高每股利率和收益来提高Medtronic的财务表现. The spin-off, expected to be completed within 18 months through an IPO, aims to boost Medtronic's financial performance by improving margins and earnings per share. 糖尿病企业占美敦力公司收入的8%和营业利润的4%,将独立运作,以加速糖尿病管理的创新。 The diabetes business, which makes up 8% of Medtronic's revenue and 4% of its operating profit, will operate independently to accelerate innovation in diabetes management.